arrow
U

Ullas Batra

sir chotu ram marg
H指数:22
被引数:1,486

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Development of a Consensus-Based Risk Stratification Algorithm for HR+/HER2− Early Breast Cancer to Guide Adjuvant CDK4/6i Therapy: Outcomes from a Multidisciplinary Workshop in India

基于共识的风险分层算法的开发,用于HR+/HER2阴性早期乳腺癌以指导辅助CDK4/6i治疗:来自印度多学科研讨会的成果

2026-09-160
OA
Real-world use of and clinical outcomes with dacomitinib as first-line therapy in Asian patients with EGFR mutation–positive locally advanced or metastatic non-small cell lung cancer: Final analysis of the ARIA study

达可替尼作为亚洲表皮生长因子受体(EGFR)突变阳性局部晚期或转移性非小细胞肺癌患者的一线疗法:ARIA研究的最终分析

2025-11-250
PRE
Savolitinib Plus Osimertinib in Epidermal Growth Factor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase 2 trial

Savolitinib 联合 Osimertinib 治疗表皮生长因子突变、MET 扩增的晚期非小细胞肺癌:一项随机 II 期临床试验

2025-10-220
PRE
A Decade of Treating ALK-Rearranged Non-Small Cell Lung Cancer in a Lower Middle-Income Country: Changing Patterns and Improving Survival

十年来在中低收入国家治疗ALK重排非小细胞肺癌:治疗模式的转变与生存改善

2025-10-170
OA
First-line pembrolizumab for metastatic NSCLC in lower-middle-income countries: bridging the efficacy-effectiveness gap

一线帕博利珠单抗治疗低收入和中等收入国家转移性非小细胞肺癌:弥合疗效-实效差距

2025-09-050
OA
Cancer Trials Ecosystem in India-Ready for Prime Time?
2024-06-011
OA
Savolitinib (savo) plus osimertinib (osi) vs savo plus placebo (PBO) in patients (pts) with EGFR-mutated (EGFRm), MET-amplified advanced NSCLC with progression on osi
2024-04-050
PRE